ClinicalTrials.Veeva

Menu

AVAPS-AE Efficacy Study

Philips logo

Philips

Status

Completed

Conditions

Obesity Hypoventilation Syndrome

Treatments

Device: Respironics OmniLab Advanced CPAP mode
Device: Respironics OnmiLab BiPAP S mode
Device: AVAPS-AE Mode of Therapy

Study type

Interventional

Funder types

Industry

Identifiers

NCT01368614
HRC-1006-AVAPS-AE-MS

Details and patient eligibility

About

The purpose of this study is to evaluate the feasibility of using of the Average Volume Assured Pressure Support (AVAPS-AE) mode versus Continuous Positive Airway Pressure (CPAP) and bilevel pressure support ventilation (PSV) modes of ventilation in patients diagnosed with Obesity Hypoventilation syndrome (OHS).

The investigators believe the use of the AVAPS-AE mode of ventilation after 6 weeks will yield daytime gas exchange values which are equivalent or no worse when compared to using CPAP and bilevel PSV modes of ventilation in the OHS population.

Enrollment

90 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age greater than or equal to 18 years of age; less than or equal to 70 years of age

  • Diagnosis of Obesity Hypoventilation Syndrome via a diagnostic sleep study in the past 3 months but have not initiated therapy

    • BMI greater than or equal to 30 kg/m2
    • Daytime PaCO2 greater than or equal to 45 mmHg
    • Apnea Hypopnea index (AHI) > 5
  • Daytime pH > 7.35

  • Forced Expiratory Volume at 1 second / forced vital capacity (FEV1/FVC) > 70%

Exclusion criteria

  • Acutely ill, medically complicated or who are medically stable, or as otherwise determined by the investigator
  • Respiratory alkalosis (pH > 7.45), per investigator discretion
  • Emergency admissions on chronic respiratory failure
  • Hospitalization for respiratory exacerbation < 6 weeks prior to screening visit
  • Participants in whom PAP therapy is otherwise medically contraindicated
  • Impaired upper airway function. For example, obstruction due to infections(laryngitis, epiglottis), craniofacial malformations, tumors, uvulopalatopharyngoplasty, presence of tracheostomy, or bilateral vocal cord palsy that does not allow tolerance of Non-invasive positive pressure ventilation (NPPV)
  • Facial trauma, burns, surgery or anatomical abnormalities interfering with mask fit.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

90 participants in 3 patient groups

AVAPS-AE
Experimental group
Description:
AVAPS-AE Mode of ventilation
Treatment:
Device: AVAPS-AE Mode of Therapy
Respironics OmniLab Advanced BiPAP S mode
Active Comparator group
Description:
OmniLab Advanced BiPAP S Mode of ventilation
Treatment:
Device: Respironics OnmiLab BiPAP S mode
Respironics OmniLab Advanced CPAP mode
Active Comparator group
Description:
OmniLab Advanced CPAP Mode of ventilation
Treatment:
Device: Respironics OmniLab Advanced CPAP mode

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems